Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -67% Improvement Relative Risk HCQ for COVID-19  Kalligeros et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 108 patients in the USA Higher mortality with HCQ (not stat. sig., p=0.57) c19hcq.org Kalligeros et al., J. Global Antimicro.., Aug 2020 Favors HCQ Favors control

Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study

Kalligeros et al., Journal of Global Antimicrobial Resistance, doi:10.1016/j.jgar.2020.07.018
Aug 2020  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Small retrospective database analysis of 36 patients receiving HCQ not showing significant differences. Confounding by indication is likely.
risk of death, 67.0% higher, HR 1.67, p = 0.57, treatment 36, control 72.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kalligeros et al., 5 Aug 2020, retrospective, USA, peer-reviewed, 13 authors, average treatment delay 6.0 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study
Markos Kalligeros, Fadi Shehadeh, Eleftheria Atalla, Evangelia K Mylona, Su Aung, Aakriti Pandita, Jerry Larkin, Martha Sanchez, Francine Touzard-Romo, Amy Brotherton, Rajeev Shah, Cheston B Cunha, Eleftherios Mylonakis
Journal of Global Antimicrobial Resistance, doi:10.1016/j.jgar.2020.07.018
To assess the efficacy and safety of hydroxychloroquine with or without azithromycin) in hospitalized adult patients with COVID-19. Methods: We utilized a hospital based prospective data registry. The primary end point was to assess the impact of hydroxychloroquine with or without azithromycin, on outcome, length of hospitalization, and time to clinical improvement. We utilized treatment effects with inverse-probability-weighting and Cox proportional hazards models. All analyses accounted for age, gender, race, severity on admission, days from symptoms onset and chronic comorbidities. Results: 36 patients received hydroxychloroquine and were age-and sex-matched to 72 patients with COVID-19 who received supportive care. Compared to supportive care, the use of HCQ did not shorten the time to clinical improvement (+0.23 days; 95% CI: À1.8-2.3 days) nor did it shorten the duration of hospital stay (+0.91 days; 95% CI: À1.1-2.9 days). Additionally, HCQ did not decrease the risk of COVID-19 in-hospital death (aHR 1.67; 95% CI: 0.29-9.36). Finally, we observed a slight QTc prolongation from a baseline of 444 AE 26 ms to 464 AE 32 ms (meanAESD) among patients receiving hydroxychloroquine with or without azithromycin. Conclusion: This study did not yield benefits from hydroxychloroquine use in patients with COVID-19 and monitoring for adverse events is warranted. Nevertheless, the treatment was safely studied under the guidance of an antimicrobial stewardship program.
Ethical approval This study received ethical approval from the Institutional Review Board (IRB) of the Rhode Island Hospital (Providence, RI, USA) [ref. #005120]. Appendix A. Supplementary data Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.jgar.2020.07.018.
References
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational study of hydroxychloroquine in hospitalized patients with COVID-19, N Engl J Med, doi:10.1056/NEJMoa2012410
Magagnoli, Narendran, Pereira, Cummings, Hardin et al., Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19, medRxiv, doi:10.1101/2020.04.16.20065920
Mahevas, Tran, Roumier, Chabrol, Paule et al., No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial, medRxiv, doi:10.1101/2020.04.10.20060699
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Yao, Ye, Zhang, Cui, Huang et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis, doi:10.1093/cid/ciaa237
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit